Dermira, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2018 12 months to Dec 31, 2018	FY2017 12 months to Dec 31, 2017	FY2016 12 months to Dec 31, 2016	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014
Net loss
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation
Loss on disposal of property and equipment
Acquired in-process research and development
Amortization of discount for payments related to acquired in-process research and development
Net amortization of premiums on available-for-sale securities
Amortization of bank term loan issuance costs
Revaluation of convertible preferred stock warrant liability
Amortization of convertible note discount and issuance costs
Common stock issued in connection with license agreement
Impairment of intangible assets
Loss on extinguishment of debt
Changes in assets and liabilities:
Trade and other receivables, net
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued liabilities
Refund liability
Other long-term liabilities
Deferred revenue
Deferred taxes

Purchases of available-for-sale securities
Net cash used in operating activities
Cash flows from investing activities
Purchases of available-for-sale securities
Maturities of available-for-sale securities
Acquisition of in-process research and development
Increase in restricted cash
Purchase of property and equipment
Net proceeds from issuance of convertible preferred stock
Proceeds from initial public offering, net of commissions
Payment of initial public offering costs
Proceeds from private placement concurrent with initial public offering
Net cash used in investing activities

Cash flows from financing activities
Net proceeds from issuance of common stock in connection with equity financings
Net proceeds from issuance of convertible notes
Net proceeds from issuance of common stock in connection with equity awards
Payment to extinguish term loan
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Net cash provided by financing activities

Net proceeds from term loan
Net increase (decrease) in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash at beginning of year
Cash and cash equivalents and restricted cash at end of year
Supplemental disclosure of cash flow information
Interest paid
Supplemental disclosure of noncash investing activities
Conversion of preferred stock into common stock
Reclassification of preferred stock warrant liability into additional paid-in-capital
Acquisition of in-process research and development
Acquisition of property and equipment under accounts payable and accrued liabilities

Comments